Meeting
2015 ASCO Annual Meeting
A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
Authors
Geoffrey Shapiro
Dana-Farber Cancer Institute, Boston, MA
Geoffrey Shapiro , James Walter Mier , John Frederick Hilton , Leena Gandhi , Nicole G. Chau , Andrea J. Bullock , Jeffrey G Supko , Sigitas Jonas Verselis , Kayla Murgo , Susan Gotthardt , Andrew Wolanski , W. James Alexander , Ashok Kumar , Sylvia Adell Holden , Karima Chafai-Fadela , Siya Ram , Krishna E. Menon , Cameron Sze
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT01664000
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS2613)
DOI
10.1200/jco.2015.33.15_suppl.tps2613
Abstract #
TPS2613
Poster Bd #
323a
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu
Poster
2016 ASCO Annual Meeting
A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
First Author: Alex A. Adjei
Poster
2013 ASCO Annual Meeting
A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors.
First Author: Andrew DJ Pearson